Bridged heterocyclic group substituted pyrimidine compound and its preparation method and medical use

By designing bridge heterocyclyl-substituted pyrimidine compounds, the problem of difficulty in inhibiting JAK1 and TYK2 in the prior art is solved, and effective treatment of related diseases is achieved, especially in inflammation and cancer, which significantly improves the therapeutic effect.

CN115087640BActive Publication Date: 2024-11-05NAT INST OF PHARMA R & D CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280002343.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-01-14
Filing Date
2022-01-12
Publication Date
2024-11-05
Estimated Expiration
2042-01-12

AI Technical Summary

Technical Problem

The existing JAK1 and TYK2 inhibitors are difficult to effectively inhibit these two kinases at the same time, limiting the therapeutic effect on related diseases.

Method used

A series of bridge heterocyclyl-substituted pyrimidine compounds were designed and synthesized to significantly inhibit their activity by contacting JAK1 and TYK2 and developed as a drug for the treatment of diseases associated with JAK1 and TYK2 activities.

Benefits of technology

This compound shows outstanding JAK1 and TYK2 inhibitory activities, and has potential effects on the treatment of inflammation, autoimmune diseases and cancer, especially in rheumatoid arthritis, psoriatic arthritis, inflammatory enteritis, etc. Effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FDA0004901981680000011
    Figure FDA0004901981680000011
  • Figure FDA0004901981680000012
    Figure FDA0004901981680000012
  • Figure FDA0004901981680000021
    Figure FDA0004901981680000021
Patent Text Reader

Abstract

A bridged heterocyclic group-substituted pyrimidine compound, a preparation method thereof and a pharmaceutical use thereof. The compound or a pharmaceutical composition comprising the compound can be used as a JAK1 and TYK2 kinase inhibitor for treating diseases associated with JAK1 and TYK2 kinase activity, such as inflammation, autoimmune diseases, cancer, etc.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a bridged heterocyclic group-substituted pyrimidine compound, a preparation method thereof, a pharmaceutical composition containing the same, and use thereof for regulating the activities of Janus kinase 1 (JAK1) and tyrosine protein kinase 2 (TYK2) and for treating and / or preventing diseases associated with the activities of JAK1 and TYK2. Background Art

[0002] The intracellular signal transduction process is an effective way for cells to respond to external stimuli and ultimately induce specific biological effects. Cytokines can transmit intracellular signals through a variety of signal transduction pathways, thereby participating in the regulation of many important biological functions related to hematopoiesis and immunity. The Janus kinase (JAK) family and transcription activator (STAT) in protein tyrosine kinase play an important role in the cytokine signal transduction process (J.Immunol.2015,194,21).

[0003] The Janus kinase (JAK) family plays a role in cytokine-dependent regulation of cell proliferation and function involved in immune responses. Currently, there are four known mammalian JAK family members: JAK1 (also known as Janus kinase-1), JAK2 (also known as Janus kinase-2), JAK3 (also known as Janus kinase, leukocyte, JAKL1, L-JAK and Janus kinase-3), Tyk2 (also known as protein-tyrosine kinase 2). JAK1, JAK2 and Tyk2 are widely present in various tissues and cells, while JAK3 is only present in the bone marrow and lymphatic system (J. Med. Chem. 2014, 57, 5023).

[0004] Tyk2 is the first JAK kinase discovered, plays an important role in regulating the biological response to IL-12 and bacterial lipopolysaccharide (LPS), and is also involved in the signal transduction pathways mediated by IL-6, IL-10 and IL-12. Targeting Tyk2 can be a new strategy for treating diseases mediated by IL-12, IL-23, or type I IFN, including but not limited to rheumatoid arthritis, multiple sclerosis, lupus, psoriasis, psoriatic arthritis, inflammatory bowel inflammation, uveitis, sarcoidosis, lupus erythematosus and cancer.

[0005] JAK1 plays an important role in regulating the biological response functions of various cytokine receptor families. JAK1 knockout mice have an early postnatal lethal factor phenotype and their nervous system is also damaged, resulting in congenital defects in young mice. Studies have shown that JAK1 knockout mice have secretion defects of thymocytes and B cells, and the response of JAK1 knockout tissues to LIF, IL-6, and IL-10 is significantly weakened. Clinical trials have shown that JAK1 inhibitors have shown good efficacy in the treatment of rheumatoid arthritis, ulcerative colitis, Crohn's disease, lupus erythematosus, alopecia areata, atopic dermatitis and other inflammatory and autoimmune diseases.

[0006] After the cytokine binds to the receptor, the receptor forms a dimer, and the JAK coupled to the receptor approaches each other and activates by phosphorylation of the tyrosine residues. Then it catalyzes the phosphorylation of the tyrosine residues of the receptor itself to form a "docking site". Signal transducer and activator of transcription (STAT) is a group of cytoplasmic proteins that can bind to target gene regulation and DNA. The STAT family includes STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. STAT recognizes the "docking site" through the SH2 domain and is activated by phosphorylation of the C-terminal tyrosine residue by the JAK kinase. The activated STAT factor is transferred into the cell nucleus and plays an important role in regulating innate and acquired host immune responses.

[0007] Activation of the JAK / STAT signal transduction pathway promotes the occurrence of various diseases, including but not limited to, many abnormal immune responses, such as allergies, asthma, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, etc. It is also associated with cancers, such as leukemia (acute myeloid leukemia and acute lymphoblastic leukemia), solid tumors (uterine leiomyosarcoma, prostate cancer), etc. (Curr. Opin. Rheumatol. 2014, 26, 237).

[0008] Given the important roles that JAK1 and TYK2 play in inflammatory signaling pathways, drugs that can simultaneously inhibit these two kinases have the potential to further enhance drug efficacy and bring greater benefits to patients. Summary of the invention

[0009] After intensive research, the inventors designed and synthesized a series of bridged heterocyclic group-substituted pyrimidine compounds, and screened their JAK1 and TYK2 activities. The research results showed that the compounds have outstanding JAK1 and TYK2 inhibitory activities and can be developed as drugs for treating diseases related to JAK1 and TYK2 activities.

[0010] The object of the present invention is to provide a compound selected from the following or a pharmaceutically acceptable salt thereof:

[0011]

[0012] The present invention further provides a method for preparing the compound 1 or a pharmaceutically acceptable salt thereof, comprising the following steps:

[0013]

[0014] The hydrochloride of compound 1i is reacted with compound 1j under alkaline conditions and in the presence of a catalyst to obtain compound 1; the reagent providing alkaline conditions is preferably DIEA, and the catalyst is preferably HATU.

[0015] The present invention also provides a method for preparing the following compound 2 or a pharmaceutically acceptable salt thereof, comprising the following steps:

[0016]

[0017] Compound 1i is reacted with compound 2 under alkaline conditions and in the presence of a catalyst to obtain compound 2; the reagent providing alkaline conditions is preferably DIEA, and the catalyst is preferably HATU.

[0018] The present invention also provides a method for preparing the following compounds 1-a and / or 1-b or their pharmaceutically acceptable salts, which comprises the following steps:

[0019]

[0020] Compound 1 is separated by supercritical fluid chromatography to obtain compound 1-a and / or compound 1-b; wherein the compound 1-a has a shorter retention time, and the compound 1-b has a longer retention time.

[0021] The present invention further provides a method for preparing the following compounds 2-a and / or 2-b or their pharmaceutically acceptable salts, which comprises the following steps:

[0022]

[0023] Compound 2 is separated by supercritical fluid chromatography to obtain compound 2-a and / or compound 2-b; wherein the compound 2-a has a shorter retention time, and the compound 2-b has a longer retention time.

[0024] The supercritical fluid chromatography described in the present invention is a chromatography method using supercritical fluid as mobile phase. The so-called supercritical fluid refers to some substances that are neither gas nor liquid, and their physical properties are between those of gas and liquid.

[0025] The supercritical fluid chromatography described in the present invention preferably uses methanol and carbon dioxide as mobile phases, more preferably uses methanol containing ammonia and carbon dioxide as mobile phases, especially uses MeOH (0.2% NH3·H2O) / CO2 as mobile phase, and more especially uses MeOH (0.2% NH3·H2O) / CO2 with a volume ratio of 40:60 as mobile phase.

[0026] The present invention further provides a pharmaceutical composition comprising the compound according to the present invention and a pharmaceutically acceptable carrier.

[0027] The present invention further relates to use of the compound according to the present invention or a pharmaceutical composition containing the compound in the preparation of JAK1 and TYK2 inhibitors.

[0028] The present invention further relates to the use of the compound according to the present invention or its pharmaceutically acceptable salt or a pharmaceutical composition containing the same in the preparation of a medicament for preventing and / or treating a disease associated with JAK1 and TYK2 activity, wherein the disease is selected from inflammation, autoimmune diseases and cancer, the inflammation is preferably selected from rheumatoid arthritis, psoriatic arthritis, inflammatory bowel inflammation, uveitis, psoriasis and atopic dermatitis, the autoimmune disease is preferably selected from multiple sclerosis and lupus; the cancer is preferably selected from breast cancer, cervical cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, ovarian tumors, peritoneal tumors, melanoma, solid tumors, gliomas, glioblastomas, hepatocellular carcinomas, papillary nephroma, head and neck tumors, leukemia, lymphoma, myeloma and non-small cell lung cancer.

[0029] The present invention further relates to a compound according to the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the same, for use as a medicament.

[0030] The present invention further relates to the compound according to the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the same, which is used as a JAK1 and TYK2 inhibitor.

[0031] The present invention further relates to a compound according to the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the same, which is used for preventing and / or treating a disease associated with JAK1 and TYK2 activity, wherein the disease is selected from inflammation, autoimmune diseases and cancer, the inflammation is preferably selected from rheumatoid arthritis, psoriatic arthritis, inflammatory bowel inflammation, uveitis, psoriasis and atopic dermatitis, the autoimmune disease is preferably selected from multiple sclerosis and lupus; the cancer is preferably selected from breast cancer, cervical cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, ovarian tumors, peritoneal tumors, melanoma, solid tumors, gliomas, glioblastomas, hepatocellular carcinomas, papillary nephroma, head and neck tumors, leukemia, lymphoma, myeloma and non-small cell lung cancer.

[0032] The present invention further relates to a method for inhibiting JAK1 and TYK2, which comprises contacting the compound according to the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, with JAK1 and TYK2.

[0033] The present invention further relates to a method for preventing and / or treating a disease associated with JAK1 and TYK2 activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, wherein the disease is selected from inflammation, autoimmune diseases and cancer, the inflammation is preferably selected from rheumatoid arthritis, psoriatic arthritis, inflammatory bowel inflammation, uveitis, psoriasis and atopic dermatitis, the autoimmune disease is preferably selected from multiple sclerosis and lupus; the cancer is preferably selected from breast cancer, cervical cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, ovarian tumors, peritoneal tumors, melanoma, solid tumors, gliomas, glioblastomas, hepatocellular carcinomas, papillary nephroma, head and neck tumors, leukemia, lymphoma, myeloma and non-small cell lung cancer.

[0034] According to the conventional method in the field of the present invention, the compounds of the present invention can form pharmaceutically acceptable acid addition salts with acids. The acid includes inorganic acids and organic acids, and particularly preferably hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid, etc.

[0035] According to the conventional methods in the field of the present invention, the compounds of the present invention can form pharmaceutically acceptable basic addition salts with bases. The bases include inorganic bases and organic bases, and acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, etc., and acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, etc.

[0036] The pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, such as tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and such compositions may contain one or more ingredients selected from the following: sweeteners, flavoring agents, colorants and preservatives to provide pleasing and palatable pharmaceutical preparations. Tablets contain the active ingredient and non-toxic pharmaceutically acceptable excipients suitable for preparing tablets for mixing. These excipients may be inert excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating agents and disintegrants such as microcrystalline cellulose, crosslinked sodium carboxymethyl cellulose, corn starch or alginic acid; binders such as starch, gelatin, polyvinyl pyrrolidone or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. These tablets may be uncoated or may be coated by known techniques which mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained release action over a longer period of time. For example, water soluble taste masking materials such as hydroxypropylmethylcellulose or hydroxypropylcellulose, or time extending materials such as ethylcellulose, cellulose acetate butyrate may be used.

[0037] Oral preparations may also be provided in hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or in soft gelatin capsules wherein the active ingredient is mixed with a water-soluble carrier such as polyethylene glycol or an oily vehicle such as peanut oil, liquid paraffin or olive oil.

[0038] Aqueous suspensions contain the active substance and excipients suitable for preparing aqueous suspensions for mixing. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone and gum arabic; dispersants or wetting agents, which may be naturally occurring phosphatides such as lecithin, or condensation products of alkylene oxides with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain fatty alcohols, for example, heptadecaethyleneoxy cetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, for example, polyethylene oxide sorbitan monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene oxide dehydrated sorbitan monooleate. The aqueous suspension may also contain one or more preservatives, for example ethylparaben or n-propylparaben, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, for example sucrose, saccharin or aspartame.

[0039] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil such as peanut oil, olive oil, sesame oil or coconut oil, or a mineral oil such as liquid paraffin. The oil suspension may contain a thickener such as beeswax, hard paraffin or cetyl alcohol. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions may be preserved by adding an antioxidant such as butylated hydroxyanisole or alpha-tocopherol.

[0040] Dispersible powders and granules suitable for preparing aqueous suspensions may provide the active ingredient by adding water and a dispersant or wetting agent, suspending agent or one or more preservatives for mixing. Suitable dispersants or wetting agents and suspending agents are as described above. Other excipients such as sweeteners, flavoring agents and coloring agents may also be added. These compositions may be preserved by adding an antioxidant such as ascorbic acid.

[0041] The pharmaceutical composition of the present invention can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil such as olive oil or peanut oil, or a mineral oil such as liquid paraffin or a mixture thereof. Suitable emulsifiers can be naturally occurring phospholipids, such as soybean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of the partial esters and ethylene oxide, such as polyethylene oxide sorbitol monooleate. Emulsions can also contain sweeteners, flavoring agents, preservatives, and antioxidants. Syrups and elixirs prepared with sweeteners such as glycerol, propylene glycol, sorbitol, or sucrose can be used. Such preparations can also contain a demulcent, a preservative, a coloring agent, and an antioxidant.

[0042] The pharmaceutical composition of the present invention may be in the form of a sterile injectable aqueous solution. Acceptable vehicles and solvents that may be used are water, Ringer's solution and isotonic sodium chloride solution. The sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and processed to form a microemulsion. The injection or microemulsion may be injected into the patient's bloodstream by local mass injection. Alternatively, the solution and microemulsion may be preferably administered in a manner that maintains a constant circulating concentration of the compound of the present invention. To maintain this constant concentration, a continuous intravenous drug delivery device may be used.

[0043] The pharmaceutical composition of the present invention can be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared by known techniques with the above-mentioned suitable dispersants or wetting agents and suspending agents. The sterile injection preparation can also be a sterile injection solution or suspension prepared in a non-toxic parenteral acceptable diluent or solvent, such as a solution prepared in 1,3-butanediol. In addition, sterile fixed oil can be conveniently used as a solvent or suspension medium. For this purpose, any blended fixed oil including synthetic glycerol mono- or di-esters can be used. In addition, fatty acids such as oleic acid can also be used to prepare injections.

[0044] The compounds of the invention may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions may be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and which will dissolve in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, polyethylene glycols of various molecular weights and mixtures of fatty acid esters of polyethylene glycol.

[0045] It is well known to those skilled in the art that the dosage of a drug depends on a variety of factors, including but not limited to the following factors: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health condition, the patient's behavior, the patient's diet, the administration time, the administration method, the excretion rate, the combination of drugs, etc. In addition, the best treatment method, such as the mode of treatment, the daily dosage of the compound or the type of pharmaceutically acceptable salt, can be verified according to traditional treatment plans.

[0046] The present invention may contain a compound, and a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient, mixed with a pharmaceutically acceptable carrier or excipient to prepare a composition, and prepared into a clinically acceptable dosage form.

[0047] The derivatives of the present invention can be used in combination with other active ingredients as long as they do not produce other adverse effects, such as allergic reactions, etc. The compounds of the present invention can be used as the sole active ingredient or in combination with other drugs for treating diseases related to JAK1 and TYK2 activity. Combination therapy is achieved by administering the individual therapeutic components simultaneously, separately or sequentially.

[0048] In this article, "pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0049] As used herein, "pharmaceutically acceptable salts" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 This is a graph showing the pharmacodynamic score results of the compounds of the present invention in rats in AIA. DETAILED DESCRIPTION

[0051] The present invention is further described below in conjunction with examples, but these examples are not intended to limit the scope of the present invention.

[0052] The structures of the compounds were determined by nuclear magnetic resonance (MR) and / or mass spectrometry (MS). -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker dps300 nuclear magnetic spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the measuring solvent, and tetramethylsilane (TMS) as the internal standard.

[0053] MS was measured using a 1100 Series LC / MSD Trap (ESI) mass spectrometer (manufacturer: Agilent).

[0054] Unless otherwise specified in the examples, the preparative liquid phase was performed using LC3000 HPLC and LC6000 HPLC (manufacturer: Chuangxin Tongheng). The chromatographic column was Daisogel C18 10 μm 60A (20 mm×250 mm). The mobile phase was acetonitrile, water (0.05% formic acid).

[0055] High performance liquid chromatography (HPLC) was performed using Shimadzu LC-20AD high pressure liquid chromatograph (Agilent TC-C18 250×4.6 mm 5 μm column) and Shimadzu LC-2010AHT high pressure liquid chromatograph (Phenomenex C18 250×4.6 mm 5 μm column).

[0056] The thin layer chromatography silica gel plate used was Qingdao Ocean Chemical GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) had a specification of 0.15 mm to 0.2 mm, and the specification used for thin layer chromatography separation and purification products was 0.4 mm to 0.5 mm.

[0057] Column chromatography generally uses Qingdao Marine Silica Gel 100-200 mesh and 200-300 mesh silica gel as the carrier.

[0058] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from online shopping malls, Beijing Coupling, Sigma, Bailingwei, Yishiming, Shanghai Shuya, Inokai, Nanjing Yaoshi, Anaiji Chemical and other companies.

[0059] Unless otherwise specified in the examples, the reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.

[0060] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1L.

[0061] A CEM Discover SP microwave reactor was used for the microwave reaction.

[0062] Unless otherwise specified in the examples, the solution refers to an aqueous solution.

[0063] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.

[0064] The reaction progress in the embodiment is monitored by thin layer chromatography (TLC), and the developing solvent systems used in the reaction are: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, D: acetone, and the volume ratio of the solvent is adjusted according to the polarity of the compound.

[0065] The eluent system of column chromatography and the developing solvent system of thin layer chromatography used for purifying compounds include: A: dichloromethane and methanol system, B: petroleum ether, ethyl acetate and dichloromethane system, C: petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.

[0066] Example

[0067] Example 1: Preparation of ((1S,2R)-2-fluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone (1)

[0068]

[0069]

[0070] Step 1: Synthesis of tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (1b)

[0071] At -78°C, under nitrogen atmosphere, potassium hexamethyldisilazide (KHMDS) (10.7 mL, 10.7 mmol) was added to a mixture of tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (2.00 g, 8.88 mmol) in anhydrous tetrahydrofuran (30 mL), and stirred at -78°C for 0.5 hour. Then, N-phenylbis(trifluoromethanesulfonyl)imide (3.82 g, 10.7 mmol) in anhydrous tetrahydrofuran (20 mL) was added dropwise, and after the addition was completed, the mixture was stirred at -78°C for 2 hours. Add saturated aqueous ammonium chloride solution (20 mL) to quench, extract with ethyl acetate (30 mL×3), wash the organic phase with potassium hydroxide solution (1 mol / L) and saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The residual liquid is purified by flash column chromatography (mobile phase: petroleum ether / ethyl acetate, 10 / 1 to 2 / 1) to obtain 3.10 g of the title compound as a light yellow oily liquid. Yield: 97.8%.

[0072] Step 2: Synthesis of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (1d)

[0073] At room temperature and under nitrogen atmosphere, Pd(dppf)Cl2 dichloromethane complex (423 mg, 0.518 mmol) was added to a solution of compound 1b (3.70 g, 10.4 mmol), potassium acetate (3.05 g, 31.1 mmol) and biboronic acid pinacol ester (1c) (2.90 g, 11.4 mmol) in dioxane (50 mL), and stirred at 80°C overnight. The solvent was dried by spin drying, added to water (40 mL), extracted with ethyl acetate (50 mL×3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residual liquid was purified by flash column chromatography (mobile phase: petroleum ether / ethyl acetate = 10 / 1 to 2 / 1) to obtain 1.20 g of the title compound as a yellow oily liquid. Yield: 34.6%.

[0074] Step 3: Synthesis of tert-butyl 3-(2-chloropyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (1f)

[0075] At room temperature and under nitrogen atmosphere, Pd(dppf)Cl2 (262 mg, 0.358 mmol) was added to a mixed solution of compound 1d (1.20 g, 3.58 mmol), potassium carbonate (1.24 g, 8.95 mmol) and 2,4-dichloropyrimidine (1e) (534 mg, 3.58 mmol) in dioxane (40 mL) and water (10 mL), and stirred at 80°C overnight. The solvent was dried by spin drying, added to water (40 mL), extracted with ethyl acetate (50 mL×3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residual liquid was purified by flash column chromatography (mobile phase: petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to obtain 830 mg of the title compound as a yellow oily liquid. Yield: 72.1%.

[0076] Step 4: Synthesis of tert-butyl 3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (1h)

[0077] At room temperature, p-toluenesulfonic acid (TsOH) (37.3 mg, 0.217 mmol) was added to a solution of compound 1f (700 mg, 2.17 mmol) and 1-methyl-1H-pyrazol-4-amine (1 g) (211 mg, 2.17 mmol) in dioxane (10 mL), and stirred at 90°C overnight. The solvent was dried, added to water (40 mL), extracted with ethyl acetate (50 mL×3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residual liquid was subjected to flash column chromatography (mobile phase: petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to obtain 600 mg of the title compound as a brown oily liquid. Yield: 72.4%.

[0078] Step 5: Synthesis of 4-(8-azabicyclo[3.2.1]oct-2-en-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine hydrochloride (1i)

[0079] At room temperature, HCl / 1,4-dioxane (6 mL, 4 M) was added to a solution of compound 1h (200 mg, 0.524 mmol) in dichloromethane (6 mL), stirred for 30 minutes, and concentrated at low temperature to obtain 157 mg of the crude title compound as a white solid.

[0080] Step 6: Synthesis of ((1S,2R)-2-fluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone (1)

[0081] 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (224 mg, 0.590 mmol) was added to a solution of (1S,2R)-2-fluorocyclopropane-1-carboxylic acid (1j) (51 mg, 0.492 mmol) in N,N-dimethylformamide (10 mL) at room temperature, and the mixture was stirred at room temperature for 30 minutes. Compound 1i (132 mg, 0.414 mmol) and N,N-diisopropylethylamine (DIEA) (190 mg, 1.48 mmol) were added, and the mixture was stirred at room temperature overnight. Add water (50 mL), extract with ethyl acetate (30 mL×3), wash the organic phase with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The residue is purified by preparative liquid chromatography (column: 30 mm×250 mm; filler: C18, 10 μm; method: 2-22 min, acetonitrile 10-40%; wavelength: 254 nm; flow rate: 45 mL / min; mobile phase: acetonitrile, water) to obtain 95.0 mg of the title compound as a yellow solid. Yield: 59.4%.

[0082] LC-MS: m / z 369[M+H] + ;

[0083] 1 H NMR (300MHz, DMSO-d6): δppm 9.34(s, 1H), 8.34-8.32(m, 1H), 7.81(s, 1H), 7.49(s, 1H), 7.28-7.11( m, 1H), 6.84-6.78 (m, 1H), 5.94-4.61 (m, 3H), 3.45 (s, 3H), 2.92-2.83 ( m, 1H), 2.63-2.49 (m, 2H), 2.39-2.25 (m, 1H), 2.18-2.04 (m, 1H), 2.01- 1.83 (m, 1H), 1.75-1.63 (m, 1H), 1.37-1.19 (m, 1H), 1.11-1.07 (m, 1H).

[0084] Examples 1-a and 1-b: Preparation of ((1S, 2R)-2-fluorocyclopropyl)((1S, 5R)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone and ((1S, 2R)-2-fluorocyclopropyl)((1R, 5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone

[0085]

[0086] Compounds 1-a and 1-b were separated from compound 1 by supercritical fluid chromatography (SFC).

[0087] SFC separation conditions: chromatographic column model: AD-H 4.6 mm x 250 mm, 5 μm, mobile phase: MeOH (0.2% NH 3 · H 2 O) / CO 2 = 40:60, flow rate: 40 g / min, column temperature: 40°C.

[0088] Compound 1-a:

[0089] Retention time: 14.97min.

[0090] LC-MS: m / z 369[M+H] + .

[0091] 1 H NMR (300MHz, DMSO-d6): 9.32 (s, 1H), 8.31 (d, J=5.20, 1H), 7.79 (d, J=5.60, 1H) ,7.47(s,1H),7.17-7.14(m,1H),6.80-6.77(m,1H),5.00-4.61(m,3H),3.77(s , 3H), 2.90-2.80(m, 1H), 2.62-2.47(m, 2H), 2.36-2.30(m, 1H), 2.22-2.05(m, 1 H), 2.00-1.86 (m, 1H), 1.76-1.62 (m, 1H), 1.35-1.17 (m, 1H), 1.07-1.04 (m, 1H).

[0092] Compound 1-b:

[0093] Retention time: 17.98min.

[0094] LC-MS: m / z 369[M+H] + .

[0095] 1H NMR (300MHz, DMSO-d6): 9.36 (s, 1H), 8.35-8.33 (m, 1H), 7.82 (s, 1H), 7.51 (s , 1H), 7.30-7.05(m, 1H), 6.85-6.81(m, 1H), 4.90-4.63(m, 3H), 3.09(s, 3H), 2.95-2.85(m, 1H), 2.65-2.58(m, 2H), 2.40-2.20(m, 1H), 2.10-2.00(m, 1H), 2.00-1.86 (m, 1H), 1.76-1.62 (m, 1H), 1.42-1.33 (m, 1H), 1.19-1.07 (m, 1H).

[0096] Example 2: Preparation of ((1R,2S)-2-fluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone (2)

[0097]

[0098] The title compound 2 was prepared in the same manner as in Example 1, except that (1R, 2S)-2-fluorocyclopropane-1-carboxylic acid (2a) was used instead of (1S, 2R)-2-fluorocyclopropane-1-carboxylic acid (1j).

[0099] Preparative liquid chromatography purification method: column: 30 mm × 250 mm; filler: C18, 10 μm; method: 2-22 min, acetonitrile 10-50%; wavelength: 254 nm; flow rate: 45 mL / min; mobile phase: acetonitrile, water.

[0100] LC-MS: m / z 365 [M+H] + .

[0101] 1 H NMR (300MHz, DMSO-d6): δppm 9.34(s, 1H), 8.34-8.30(m, 1H), 7.83(s, 1H), 7.51(s, 1H), 7.18-7.12( m, 1H), 6.84-6.80 (m, 1H), 4.98-4.64 (m, 3H), 3.80 (s, 3H), 2.93-2.87 ( m, 1H), 2.68-2.50 (m, 2H), 2.35-2.24 (m, 1H), 2.08-2.05 (m, 1H), 1.92- 1.84 (m, 1H), 1.80-1.61 (m, 1H), 1.41-1.34 (m, 1H), 1.18-1.05 (m, 1H).

[0102] Examples 2-a and 2-b: Preparation of ((1R, 2S)-2-fluorocyclopropyl)((1S, 5R)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone and ((1R, 2S)-2-fluorocyclopropyl)((1R, 5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone

[0103]

[0104] Compounds 2-a and 2-b were separated from compound 2 by supercritical fluid chromatography (SFC).

[0105] SFC separation conditions: chromatographic column model: AD-H 4.6 mm x 250 mm, 5 μm, mobile phase: MeOH (0.2% NH 3 · H 2 O) / CO 2 = 40:60, flow rate: 40 g / min, column temperature: 40°C.

[0106] Compound 2-a:

[0107] Retention time: 12.53min.

[0108] LC-MS: m / z 369[M+H] + .

[0109] 1 H NMR (400MHz, DMSO): δ9.35 (s, 1H), 8.35-8.32 (m, 1H), 7.82 (s, 1H), 7.50 (s, 1H), 7.19-7.15(m, 1H), 6.85-6.81(m, 1H), 4.90-4.63(m, 3H), 3.81(s, 3H), 2 .91-2.89(m, 1H), 2.67-2.51(m, 2H), 2.47-2.29(m, 1H), 2.09-2.04(m, 1H), 1.91-1.81 (m, 1H), 1.74-1.58 (m, 1H), 1.45-1.31 (m, 1H), 1.14-1.08 (m, 1H).

[0110] Compound 2-b:

[0111] Retention time: 15.46min.

[0112] LC-MS: m / z 369[M+H] + .

[0113] 1H NMR (400MHz, DMSO): δ9.35 (s, 1H), 8.35-8.33 (m, 1H), 7.82 (s, 1H), 7.50 (s, 1H), 7.19-7.15(m, 1H), 6.83-6.81(m, 1H), 5.03-4.65(m, 3H), 3.80(s, 3H), 2 .91-2.89(m, 1H), 2.67-2.51(m, 2H), 2.48-2.28(m, 1H), 2.10-2.01(m, 1H), 1.98-1.86 (m, 1H), 1.84-1.65 (m, 1H), 1.38-1.33 (m, 1H), 1.20-1.06 (m, 1H).

[0114] Biological evaluation

[0115] Test Example 1: Determination of the in vitro JAK1 kinase inhibitory activity of the compounds of the present invention

[0116] Experimental materials: JAK1 kinase (Invitrogen, PV4744), ATP (Promega, V915B), ADP-GloKinase Assay (Promega, V9101), IRS1 (Signalchem, I40-58-1000).

[0117] Sample preparation: The compound of the present invention and the reference substance were dissolved in DMSO solvent to prepare 10 mM stock solution. The final maximum concentration of the compound reaction was 10 μM, 3-fold dilution, 10 concentration gradients, and 2 replicate wells for each concentration gradient.

[0118] Experimental method: Echo transfer 0.1 μL of the test compound to a 384-well reaction plate (PE, 6007290), centrifuge at 1000 rpm / min for 1 min. Transfer 5 μL of JAK1 kinase (final concentration 4 nM) to a 384-well reaction plate, centrifuge at 1000 rpm / min for 1 min, and incubate at 25°C for 15 min. Transfer 5 μL of substrate mixture (1 mM ATP, IRS1 0.05 mg / ml, kinase buffer solution) to a 384-well reaction plate, centrifuge at 1000 rpm / min for 1 min, and incubate at 25°C for 60 min. Transfer 10 μL of ADP-Glo ​​to a 384-well reaction plate at 1000 rpm / min, centrifuge at 1000 rpm / min, and incubate at 25°C for 40 min. Transfer 20 μL of detection solution to a 384-well reaction plate at 1000 rpm / min, centrifuge at 1000 rpm / min, and incubate at 25°C for 40 min. The relative luminescence unit (RLU) signal was read using an Envision multi-function plate reader. The signal intensity was used to characterize the activity of the kinase.

[0119] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (half inhibitory concentration):

[0120] Y=Bottom+(Top-Bottom) / (1+10 ∧ ((LogIC 50 -X)*HillSlope));

[0121] X: Log value of compound concentration;

[0122] Y: Emission Ratio;

[0123] Bottom: lowest value, Top: highest value, HillSlope: slope;

[0124] The inhibitory activity of the compounds of the present invention on JAK1 kinase is shown in Table 1 below. 50 Values ​​between 0 and 100 nM are labeled A, 100 and 300 nM are labeled B, 300 and 1000 nM are labeled C, and values ​​greater than 1000 nM are labeled D. NT stands for not tested.

[0125] Table 1: Inhibitory activity of the compounds of the present invention on JAK1 kinase

[0126]

[0127] It can be clearly seen from the above test results that the compounds of the present invention have good in vitro anti-JAK1 kinase activity.

[0128] Experimental Example 2: Inhibition of the STAT3 signaling pathway in human whole blood by the compounds of the present invention

[0129] Experimental materials: CD3 (BD, 555335), pSTAT3 antibody (BD, 612569), IFN-2α (Biolegend, 592702).

[0130] Sample preparation: The compound of the present invention and the reference substance were dissolved in DMSO solvent to prepare 10 mM stock solution. The final maximum concentration of the compound reaction was 10 μM, 3-fold dilution, 10 concentration gradients, and 2 replicate wells for each concentration gradient.

[0131] Experimental method: After adding 20 μL of the compound of the present invention to a flow cytometer tube containing 180 μL of heparin sodium anticoagulation (BD, 352052), add 20 μL of PBS to the control, and incubate at 37°C for 30 min; add 2 μL of stimulating factor and incubate at 37°C for 20 min; add 1 mL of red blood cell lysis buffer, quickly invert 5-10 times or vortex the sample, and incubate at 37°C for 10 min; centrifuge at 600g for 6-8 min, discard the supernatant, and vortex to suspend the pellet; add 3 mL of PBS to wash the cells; centrifuge at 600g for 6-8 min, discard the supernatant; vortex to suspend the pellet; add 1 mL of membrane permeabilization solution, mix gently, and incubate on ice for 30 min; centrifuge at 600g for 6-8 min, discard the supernatant; vortex to suspend the pellet; wash the cells, add 3 mL of PBS, centrifuge at 600g for 6-8 min, discard the supernatant; vortex to suspend the pellet; repeat twice, and add 100 μL to each staining tube. PBS, add IFN-2α stimulation, and add CD3 and pSTAT3 antibodies (20μL), mix well, protect from light; incubate at room temperature for 60min. Wash cells, add 3mL PBS, centrifuge at 600g for 6-8min, discard supernatant; vortex, suspend precipitate. Suspend the precipitate in 150μL, protect from light, and prepare for flow cytometry analysis. The IC of the compound is obtained using the following nonlinear fitting formula: 50 (half inhibitory concentration):

[0132] Y=Bottom+(Top-Bottom) / (1+10 ∧ ((LogIC 50 -X)*HillSlope));

[0133] X: Log value of compound concentration;

[0134] Y: Emission Ratio;

[0135] Bottom: lowest value, Top: highest value, HillSlope: slope

[0136] The inhibitory effects of the compounds of the present invention on the TYK2 / JAK1 mediated pathway stimulated by IFN-2α are shown in Table 2 below. 50 Values ​​between 0 and 100 nM are labeled A, 100 and 300 nM are labeled B, 300 and 1000 nM are labeled C, and values ​​greater than 1000 nM are labeled D. NT stands for not tested.

[0137] Table 2: Inhibition of the compounds of the present invention on the STAT3 signaling pathway in human whole blood

[0138]

[0139] It can be seen from Table 2 that the compounds of the present invention have a good inhibitory effect on the signaling pathway mediated by TYK2 / JAK1 in human whole blood.

[0140] Test Example 3: Pharmacokinetic study in rats

[0141] Sample preparation: The compounds of Examples 1-a and 1-b were formulated with 20% cyclodextrin to prepare 0.2 mg / mL and 0.5 mg / mL solutions.

[0142] Experimental method: Male SD rats (Beijing Weitong Lihua Experimental Technology Co., Ltd.) were selected, and the intravenous dose was 1 mg / kg (intravenous injection, iv), and blood was collected from the canthal venous plexus before and 0, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours after administration. The oral dose was 5 mg / kg (oral, po), and blood was collected from the canthal venous plexus before and 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours after administration. The blood was anticoagulated with sodium heparin, centrifuged at 4°C, 3500rpm for 10 minutes, and the plasma was obtained and stored at -20°C until testing.

[0143] Accurately measure 50 μL of plasma sample melted at room temperature, place it in a 1.5 mL EP tube, add 400 μL of verapamil internal standard working solution (China Institute for Drug Control), vortex vigorously shake for 1 minute, and centrifuge at 16000 rpm for 10 minutes. Take the supernatant, filter it with a 0.22 μm organic membrane (AS081320-T, Agela Technologies), add it to the injection vial, analyze it by LC / MS (Waters UPLC I Class / TQ-S micro) to obtain the blood drug concentration, and analyze it with DAS3.3.0 software to obtain the main pharmacokinetic parameters of compounds 1-a and 1-b in rats, see Table 3 below.

[0144] Table 3 shows the pharmacokinetic parameters of compounds 1-a and 1-b in rats, where AUC <500 μg / L*h is marked as C, 500-1000 μg / L*h is marked as B, and >1000 μg / L*h is marked as A; C max The concentration of <300μg / L is marked as C, 300-500μg / L is marked as B, and >500μg / L is marked as A; T 1 / 2 Marked as B when <1h, marked as A when >1h; F marked as C when <30%, marked as B when 30-50%h, marked as A when >50%.

[0145] Table 3: Pharmacokinetic parameters of compounds 1-a and 1-b of the present invention in rats

[0146]

[0147] As can be seen from Table 3, compounds 1-a and 1-b of the present invention have good pharmacokinetic properties and are suitable for oral administration.

[0148] Test Example 4: Pharmacodynamic study of the compounds of the present invention on rat AIA

[0149] Experimental materials: Complete Freund's adjuvant (Chondrex, 7027); positive control compound PF-06700841, whose structure is Prepared according to J Med Chem, 2018, 618597-8612.

[0150] Experimental method: To investigate the in vivo efficacy of the compounds of the present invention, 8-week-old female Lewis rats (Weitong Lihua Experimental Animal Technology Co., Ltd.) were selected, and 0.1 mL of complete Freund's adjuvant was injected subcutaneously at the base of the tail. After 13 days of modeling, the rats were divided into 8 groups, namely, normal group, model group, PF-06700841 low-dose group, PF-06700841 high-dose group, compound 1-a low-dose group, compound 1-a high-dose group, compound 1-b low-dose group and compound 1-b high-dose group (the test compound was prepared into 0.1 mg / mL and 0.3 mg / mL concentration solutions with 20% cyclodextrin solution, respectively). The model group was given 20% cyclodextrin, the low-dose group was given 1 mg / kg of the test substance, and the high-dose group was given 3 mg / kg of the test substance. The scores were evaluated once every 2 days after administration. The scoring criteria will be as follows: 0 points: no redness or swelling; 1 point: mild redness and swelling of ankle and wrist joints; 2 points: moderate redness and swelling of ankle and wrist joints; 3 points: severe redness and swelling of the paws including the fingertips; 4 points: maximum inflammation of the limbs, including multiple joints. The scoring results are statistically analyzed by Graph prism9.0 software.

[0151] Figure 1 The figure is the result of the pharmacodynamic score of the compounds of the present invention in rats in AIA. It can be seen from the results of the in vivo pharmacodynamic experiment in the AIA model that the pharmacodynamics of the compounds 1-a and 1-b of the present invention are significantly better than the reference substance PF-06700841 in both the low-dose group and the high-dose group. At the same time, the pharmacodynamics of isomer 1-a is significantly better than that of isomer 1-b.

Claims

1. A compound selected from the following or a pharmaceutically acceptable salt thereof:

2. A method for preparing a compound of the following formula 1 or a pharmaceutically acceptable salt thereof, wherein The following steps are involved: Compound 1 is obtained by reacting the hydrochloride of compound 1i with compound 1j under alkaline conditions and in the presence of a catalyst.

3. The preparation method according to claim 2, wherein the reagent providing the alkaline condition is DIEA and the catalyst is HATU.

4. A method for preparing the compound 2 or a pharmaceutically acceptable salt thereof, wherein The following steps are involved: The hydrochloride of compound 1i is reacted with compound 2 under alkaline conditions and in the presence of a catalyst to obtain compound 2.

5. The preparation method according to claim 4, wherein the reagent providing alkaline conditions is DIEA and the catalyst is HATU.

6. A method for preparing the following compounds 1-a and / or 1-b or their pharmaceutically acceptable salts, wherein The following steps are involved: Compound 1 is separated by supercritical fluid chromatography to obtain compound 1-a and / or compound 1-b; wherein the mobile phase of the supercritical fluid chromatography is 0.2% NH 3 . H 2 O-MeOH / CO 2 =40:60; among them, the one with shorter retention time is compound 1-a, and the one with longer retention time is compound 1-b.

7. A method for preparing the following compounds 2-a and / or 2-b or their pharmaceutically acceptable salts, wherein The following steps are involved: Compound 2 is separated by supercritical fluid chromatography to obtain compound 2-a and / or compound 2-b; wherein the mobile phase of the supercritical fluid chromatography is 0.2% NH 3 . H 2 O-MeOH / CO 2 =40:60; among them, the one with shorter retention time is compound 2-a, and the one with longer retention time is compound 2-b.

8. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 8 in the preparation of a medicament for preventing and / or treating diseases associated with JAK1 and TYK2 activities.

10. The use according to claim 9, wherein the disease is selected from inflammation, autoimmune diseases and cancer.

11. The method of claim 10, wherein the inflammation is selected from rheumatoid arthritis, psoriatic arthritis, inflammatory bowel inflammation, uveitis, psoriasis and atopic dermatitis, the autoimmune disease is selected from multiple sclerosis and lupus, and the cancer is selected from breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, ovarian tumors, peritoneal tumors, melanoma, glioma, glioblastoma, head and neck tumors, leukemia, lymphoma and myeloma.

12. The use according to claim 10, wherein the cancer is hepatocellular carcinoma, papillary nephroma or non-small cell lung cancer.